Brodalumab: 5-Year US Pharmacovigilance Report-Reference-Cited by-同舟云学术

Brodalumab: 5-Year US Pharmacovigilance Report

Published:2024-05 Issue:5 Volume:14 Page:1349-1357
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Lebwohl Mark G.^ORCID,Koo John Y.^ORCID,Armstrong April W.^ORCID,Strober Bruce E.^ORCID,Martin George M.^ORCID,Rawnsley Nicole N.^ORCID,Goehring Earl L.^ORCID,Jacobson Abby A.^ORCID

Funder

Ortho Dermatologics

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01162-8.pdf

Reference15 articles.

1. Siliq [package insert]. Bridgewater, NJ: Bausch Health US, LLC; 2020.

2. Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183(6):1037–48.

3. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86.

4. Lebwohl M, Leonardi C, Armstrong A, et al. Three-year U.S. pharmacovigilance report of brodalumab [published correction appears in Dermatol Ther. 2022;35(9):e15664]. Dermatol Ther. 2021;34(6):e15105.

5. Lebwohl M, Leonardi C, Wu JJ, et al. Two-year US pharmacovigilance report on brodalumab. Dermatol Ther (Heidelb). 2021;11(1):173–80.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review;Advances in Therapy;2024-08-28

2. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29